ClinicalTrials.gg
RecruitingNCT07192016MUSTUpdated Jul 31, 2026

129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

A Phase 4 interventional study of fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Western University, Canada · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
17th of 25
60 · median 229
Started
2026
the only one that year
Phase 4
13 of 25
2 open now
Registered
25th of 25
by date
Lead sponsor
1 of 25
Western University, Canada

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 13 in phase 4, and was the 25th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting β2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:

  • Does FF/UMEC/VI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD
  • Evaluate the relationships between the ventilation defect percent and lung function test results

Participants will:

  • Take the inhaler FF/UMEC/VI once daily for 12-weeks (optional 48-weeks)
  • visit Robarts 2 times (with optional 3rd visit) for tests and imaging
Read the detailed description

This study will evaluate 60 COPD patients age 50-85 (equal numbers males and females) with persistent, moderate-severe dyspnea, poor health status and either: 1) low risk of exacerbation (n=30) or moderate-high risk of exacerbation (n=30). Two visits at baseline and 12-weeks are proposed with an optional visit at 48-weeks to assess longitudinal effects of therapy.

At all study visits participants will have vital signs recorded and undergo pre- and post-bronchodilator spirometry, plethysmography, oscillometry, pre-bronchodilator forced exhaled nitric oxide (FeNO) and post-bronchodilator diffusing capacity of the lungs for carbon monoxide (DLco). Participants will undergo pre- and post-bronchodilator 129-Xe MRI and post-bronchodilator chest computed tomography (CT). Participants will complete St. George's Respiratory Questionnaire (SGRQ), Modified Medical Research Council (mMRC), COPD Assessment Test (CAT), Borg rating of perceived exertion questionnaire will be completed before and after the six-minute walk test (6MWT). Participants will have a blood draw for complete blood count (CBC).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Pulmonary Function
  • COPD
  • 129-Xenon
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient understands study procedures and is willing to participate in the study as indicated by the patient's signature
  • provision of written, prior to any study specific procedures
  • males and females 50-85 years of age
  • stable , currently on dual therapy LAMA/LABA or ICS/LABA or initial maintenance therapy for at least 3 months
  • mMRC score ≥2 and/or CAT score ≥10
  • Low risk subgroup: participant has experienced ≤1 exacerbation in the past year and no hospitalizations for COPD High risk subgroup: participant has experienced ≥2 exacerbations in the past year
  • Female of (after menarche) must ensure that they are using an effective form of for at least 2 months prior to each imaging visit. Examples of effective birth control include:

    1. True sexual abstinence
    2. A vasectomized sexual partner
    3. Implanon®
    4. Female sterilization by tubal occlusion
    5. Effective intrauterine device (IUD)/levonogestrel intrauterine system (IUS)
    6. Depo-Provera™ injections
    7. Oral contraceptive
    8. Evra Patch™
    9. Nuvaring™
  • Female permanently sterile due to: 1) documented hysterectomy, 2) documented bilateral salpingectomy, and 3) documented bilateral oophorectomy
  • female: defined as female with no menses for 12 months without an alternative medical cause
  • Females of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test taken within 24 hr of any planned CT examination at Visit-1 through Visit 3
  • Male participants who are sexually active with a woman who can still have children, must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose

Exclusion criteria

Exclusion Criteria:

  • Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist)
  • In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia
  • Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit
  • Participant is unable to perform spirometry or plethysmography maneuvers
  • Participant is unable to perform MRI and CT breath-hold maneuvers
  • Participant has an unstable cardiovascular, gastro-intestinal, hepatic, renal, neurologic, metabolic or psychiatric disease
  • Participation in any clinical trial of an agent or procedure within three months prior to screening or during the study
  • Known history of allergy or reaction to the study drug formulation
  • Participant has a blood pressure of >150 mmHg systolic or >95 mmHg diastolic on more than 2 measurements done >5 minutes apart at Visit-1
  • Participants with a recently (\<2 months) documented diagnosis of asthma
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Participants with persistent moderate-severe COPD

    Participants with moderate to severe COPD will be evaluated during and after a twelve week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.

    Drug: fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg

Interventions

  • Drugfluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg

    Drug pages: Fluticasone furoateStudies of Fluticasone furoateFluticasone furoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GSK573719Studies of GSK573719GSK573719 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VilanterolStudies of VilanterolVilanterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The investigational drug is a single Ellipta inhaler containing 100 ug fluticasone furoate(inhaled corticosteroid), 62.5 ug umeclidinium(long-acting muscarinic antagonist) and 25 ug vilanterol(long-acting β2-adrenergic agonist). The drug is delivered in an Ellipta inhaler in a single dose once daily.

    Also known as: Trelegy

06

What researchers measure

Primary outcomes

  1. Measure the effect of FF/UMEC/VI therapy on VDP

    Measured using 129-xenon MRI ventilation defect percent

    Time frame: 12-weeks and optional 48-weeks

  2. Measure the effect of FF/UMEC/VI on FEV1

    Measured by the forced expiratory volume at 1 second

    Time frame: at 12-weeks and optional 48-weeks

Secondary outcomes

  1. Evaluate the relationship between MRI VDP and lung function

    measured using MRI ventilation defect percent and forced expiratory volume at 1 second

    Time frame: 12-weeks and optional 48-weeks

  2. Evaluate the relationship between MRI VDP and SGRQ score

    measured using 129-xenon MRI ventilation defect percent and St. George's Respiratory Questionnaire score

    Time frame: 12-weeks and optional 48-weeks

  3. Evaluate the relationship between MRI VDP and CAT score

    Measured using 129-xenon MRI ventilation defect percent and COPD Assessment Test score

    Time frame: 12-weeks and optional 48-weeks

  4. Evaluate the relationship between MRI VDP and mMRC score

    Measured using 129-xenon MRI ventilation defect percent and modified Medical Research Council questionnaire score

    Time frame: 12-weeks and optional 48-weeks

  5. Evaluate the relationship between MRI VDP and 6MWD

    Measured using 129-xenon MRI ventilation defect percent and six-minute walk distance.

    Time frame: 12-weeks and optional 48-weeks

  6. Evaluate and compare potential differences in MRI VDP response among patients with low- and high-risk of exacerbation.

    Measured using 129-xenon MRI ventilation defect percent and comparing exacerbation rates across patients with low- and high-risk of exacerbation.

    Time frame: 12-weeks and optional 48-weeks

  7. Evaluate the relationship between MRI VDP and blood inflammatory markers

    Measured using 129-xenon MRI ventilation defect percent and blood eosinophil count

    Time frame: 12-weeks and optional 48-weeks

  8. Evaluate the relationship between MRI VDP and CT measurements

    Measured using 129-xenon MRI ventilation defect percent and CT mucus-score

    Time frame: 12-weeks and optional 48-weeks

  9. Evaluate change in VDP as a predictor of annualized exacerbation rate

    Measured using change in 129-xenon MRI ventilation defect percent with annualized exacerbation rate as reported by the participant

    Time frame: 12-weeks and optional 48-weeks

  10. Evaluate the relationship between MRI VDP and lung volume

    Measured using MRI ventilation defect percent and forced vital capacity

    Time frame: 12-weeks and optional 48-weeks

  11. Evaluate the relationship between MRI VDP and CT measurements

    Measured using MRI ventilation defect percent and CT mucus-count

    Time frame: 12-weeks and optional 48-weeks

  12. Evaluate the relationship between MRI VDP and CT measurements

    Measured using MRI ventilation defect percent and CT mucus-volume

    Time frame: 12-weeks and optional 48-weeks

07

Study locations

1 of 1 sites recruiting
  • Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
    London, Ontario N6A 5B7, Canada
    Recruiting
    • Grace Parraga, PhD · Contactgparraga@uwo.ca · 519-931-5265
    • Angela Wilson · Contactawilson@robarts.ca · 519-931-5777
    • Grace Parraga, PhD · Principal investigator
08

References and documents

Publications

  • McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978 Jul 22;2(6132):241-3. doi: 10.1136/bmj.2.6132.241. PubMed 678885 ↗
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321-7. doi: 10.1164/ajrccm/145.6.1321. PubMed 1595997 ↗
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. PubMed 19720809 ↗
  • Kaushik SS, Robertson SH, Freeman MS, He M, Kelly KT, Roos JE, Rackley CR, Foster WM, McAdams HP, Driehuys B. Single-breath clinical imaging of hyperpolarized (129)Xe in the airspaces, barrier, and red blood cells using an interleaved 3D radial 1-point Dixon acquisition. Magn Reson Med. 2016 Apr;75(4):1434-43. doi: 10.1002/mrm.25675. Epub 2015 May 18. PubMed 25980630 ↗
  • Costella S, Kirby M, Maksym GN, McCormack DG, Paterson NA, Parraga G. Regional pulmonary response to a methacholine challenge using hyperpolarized (3)He magnetic resonance imaging. Respirology. 2012 Nov;17(8):1237-46. doi: 10.1111/j.1440-1843.2012.02250.x. PubMed 22889229 ↗
  • Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. Acad Radiol. 2012 Feb;19(2):141-52. doi: 10.1016/j.acra.2011.10.007. Epub 2011 Nov 21. PubMed 22104288 ↗
  • King GG, Bates J, Berger KI, Calverley P, de Melo PL, Dellaca RL, Farre R, Hall GL, Ioan I, Irvin CG, Kaczka DW, Kaminsky DA, Kurosawa H, Lombardi E, Maksym GN, Marchal F, Oppenheimer BW, Simpson SJ, Thamrin C, van den Berge M, Oostveen E. Technical standards for respiratory oscillometry. Eur Respir J. 2020 Feb 27;55(2):1900753. doi: 10.1183/13993003.00753-2019. Print 2020 Feb. PubMed 31772002 ↗
  • Bhakta NR, McGowan A, Ramsey KA, Borg B, Kivastik J, Knight SL, Sylvester K, Burgos F, Swenson ER, McCarthy K, Cooper BG, Garcia-Rio F, Skloot G, McCormack M, Mottram C, Irvin CG, Steenbruggen I, Coates AL, Kaminsky DA. European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. Eur Respir J. 2023 Oct 12;62(4):2201519. doi: 10.1183/13993003.01519-2022. Print 2023 Oct. PubMed 37500112 ↗
  • Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017 Jan 3;49(1):1600016. doi: 10.1183/13993003.00016-2016. Print 2017 Jan. PubMed 28049168 ↗
  • Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST. PubMed 31613151 ↗
  • Schmidt MH, Marshall J, Downie J, Hadskis MR. Pediatric magnetic resonance research and the minimal-risk standard. IRB. 2011 Sep-Oct;33(5):1-6. No abstract available. PubMed 22043743 ↗
  • Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NA, McCormack DG, Parraga G. Hyperpolarized 129Xe magnetic resonance imaging: tolerability in healthy volunteers and subjects with pulmonary disease. Acad Radiol. 2012 Aug;19(8):941-51. doi: 10.1016/j.acra.2012.03.018. Epub 2012 May 15. PubMed 22591724 ↗
  • Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nouls JC, Kaushik SS, Firszt R, Willis C, Kelly KT, Wolber J, Kraft M, McAdams HP. Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients. Radiology. 2012 Jan;262(1):279-89. doi: 10.1148/radiol.11102172. Epub 2011 Nov 4. PubMed 22056683 ↗
  • Kirby M, Pike D, Sin DD, Coxson HO, McCormack DG, Parraga G. COPD: Do Imaging Measurements of Emphysema and Airway Disease Explain Symptoms and Exercise Capacity? Radiology. 2015 Dec;277(3):872-80. doi: 10.1148/radiol.2015150037. Epub 2015 Jul 7. PubMed 26151081 ↗
  • Kirby M, Eddy RL, Pike D, Svenningsen S, Coxson HO, Sin DD, McCormack DG, Parraga G; Canadian Respiratory Research Network. MRI ventilation abnormalities predict quality-of-life and lung function changes in mild-to-moderate COPD: longitudinal TINCan study. Thorax. 2017 May;72(5):475-477. doi: 10.1136/thoraxjnl-2016-209770. Epub 2017 Mar 3. PubMed 28258250 ↗
  • Kirby M, Kanhere N, Etemad-Rezai R, McCormack DG, Parraga G. Hyperpolarized helium-3 magnetic resonance imaging of chronic obstructive pulmonary disease exacerbation. J Magn Reson Imaging. 2013 May;37(5):1223-7. doi: 10.1002/jmri.23896. Epub 2012 Nov 2. PubMed 23124806 ↗
  • Kirby M, Svenningsen S, Kanhere N, Owrangi A, Wheatley A, Coxson HO, Santyr GE, Paterson NA, McCormack DG, Parraga G. Pulmonary ventilation visualized using hyperpolarized helium-3 and xenon-129 magnetic resonance imaging: differences in COPD and relationship to emphysema. J Appl Physiol (1985). 2013 Mar 15;114(6):707-15. doi: 10.1152/japplphysiol.01206.2012. Epub 2012 Dec 13. PubMed 23239874 ↗
  • Kirby M, Mathew L, Wheatley A, Santyr GE, McCormack DG, Parraga G. Chronic obstructive pulmonary disease: longitudinal hyperpolarized (3)He MR imaging. Radiology. 2010 Jul;256(1):280-9. doi: 10.1148/radiol.10091937. PubMed 20574101 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 17 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 25, 2025
StartActual
Apr 24, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Oct 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192016
Responsible party
Dr. Grace Parraga (Principal Investigator, Western University, Canada) — Principal investigator
First posted
Sep 25, 2025
Start date
Apr 24, 2026
Primary completion
Sep 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 31, 2026

Study contacts

Grace E Parraga, PhD
Contact
gparraga@uwo.ca
519-931-5265
Angela Wilson, RRT
Contact
awilson@robarts.ca
519-931-5777 ext. 24197
Grace Parraga, PhD
principal investigator · Robarts Research Institute, The University of Western Ontario

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · GSK573719 · Vilanterol

Start the discussion